Defiance Nasdaq Junior Biotechnology ETF
IBBJ
IBBJ was delisted on the 2nd of December, 2021.
9 hedge funds and large institutions have $887K invested in Defiance Nasdaq Junior Biotechnology ETF in 2021 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 2 increasing their positions, 1 reducing their positions, and 1 closing their positions.
112% more capital invested
Capital invested by funds: $418K → $887K (+$469K)
100% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 1
100% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 1
13% more funds holding
Funds holding: 8 → 9 (+1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
IFG
Independent Financial Group
San Diego,
California
|
+$374K |
| 2 |
JIP
Jaffetilchin Investment Partners
Tampa,
Florida
|
+$263K |
| 3 |
TWM
Tradition Wealth Management
Edina,
Minnesota
|
+$135K |
| 4 |
Osaic Holdings
Scottsdale,
Arizona
|
+$61 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TRCT
Tower Research Capital (TRC)
New York
|
-$231K |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$19.3K |
IBBJ Hedge Fund Activity: Q3 2021 in Review
9 of the 5,728 institutional investors tracked by Wall St. Rank reported a position in Defiance Nasdaq Junior Biotechnology ETF (IBBJ) for Q3 2021, worth a combined $887K — up 112% from $418K a quarter earlier.
Buyers outnumbered sellers: 2 funds opened new IBBJ positions and 1 closed out — a net gain of 1 holder — while 2 added to existing stakes and 1 trimmed.
The largest buyer was Independent Financial Group, opening a new position worth an estimated $374K. The largest seller was Tower Research Capital (TRC), exiting entirely with an estimated $231K sold.
- 9 institutional investors held Defiance Nasdaq Junior Biotechnology ETF (IBBJ) as of Q3 2021, up from 8 in Q2 2021.
- Funds reported $887K of Defiance Nasdaq Junior Biotechnology ETF stock for Q3 2021, up 112% quarter-over-quarter.
- 2 funds opened new Defiance Nasdaq Junior Biotechnology ETF positions in Q3 2021 and 1 closed out, a net change of +1 holder.
- The largest Defiance Nasdaq Junior Biotechnology ETF buyer in Q3 2021 was Independent Financial Group, an estimated $374K added.
- The largest Defiance Nasdaq Junior Biotechnology ETF seller in Q3 2021 was Tower Research Capital (TRC), an estimated $231K sold.
Based on aggregated 13F filings for Q3 2021.